SCPS - Scopus Biopharma rockets 94% on FDA green light for CpG-STAT3siRNA trial

The FDA has approved Scopus BioPharma's ([[SCPS]] +109.7%) investigational new drug application ((IND)) for CpG-STAT3siRNA, the distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope, an independent research and treatment center for cancer, diabetes and other life-threatening diseases near Los Angeles, California. CpG-STAT3siRNA encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.

For further details see:

Scopus Biopharma rockets 94% on FDA green light for CpG-STAT3siRNA trial